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This review gives an up-to-date account of the
current state of research on neuropsychiatric
complications associated with efavirenz therapy
and critiques the methods used in previous stud-
ies. The authors suggest an extension of current
research strategies using psychophysiological con-
cepts and including behavioral regulation models.
From a practical perspective, these may contrib-
ute to better screening methods for the identifica-
tion of those at risk for neuropsychiatric compli-
cations and the improvement of neuropsychiatric
monitoring during efavirenz treatment. From a
theoretical viewpoint, the suggested research
paradigms may help to move beyond the cur-
rent state of descriptive approaches and thus
improve our limited understanding of underly-
ing mechanisms.
(The Journal of Neuropsychiatry and Clinical
Neurosciences 2010; 22:361–369)
Efavirenz is a commonly used non-nucleoside re-verse transcriptase inhibitor frequently prescribed
in combination with other antiretroviral regimens (e.g.,
protease inhibitors) for the treatment of HIV. After its
admission for pharmaceutical treatment in the United
States in 1998, efavirenz has become a cornerstone for
highly active antiretroviral therapies (HAART). Good
CNS penetration has been seen as a major strength of
antiretroviral regimens, particularly efavirenz. Accu-
mulating evidence suggests neuroprotective effects
against cognitive decline such as HIV-associated de-
mentia and other aspects of neuropsychological func-
tioning.1–4 Nevertheless, its proven effectiveness as a
first-line treatment in suppressing plasma viral load
comes along with reports of adverse central-nervous
and neuropsychiatric effects which have been fre-
quently reported after exposure to efavirenz.5–9
Types and Prevalence Rates of Efavirenz-Associated
Neuropsychiatric Effects: Current Evidence
Depression, suicidal ideation, aggressive/impulsive be-
havior, paranoid reactions, manic reactions and (largely
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anecdotal reports of) psychosis-like behavior, suicide,
and severe delusions are among the most frequently
reported psychiatric symptoms associated with efa-
virenz treatment. Dizziness, insomnia, impaired con-
centration, irritability, nervousness, somnolence, abnor-
mal dreams, and hallucinations are usually classified as
CNS symptoms. The differentiation between CNS-
related and psychiatric symptoms is rather arbitrary
and has not been consistent; in general, psychiatric
symptoms include some sort of behavioral or conscious
component. This differentiation aims to reflect differ-
ences at the symptom level but does not necessarily
imply distinct causal mechanisms.
Estimates of prevalence rates have varied over the
years in line with the progress of efavirenz toxicity
research, from early anecdotal case reports10 –15 and
cross-sectional controlled trials16 –18 to prospective
studies of larger samples19 and a growing number of
reviews.5–7,9 Recent studies have focused on the rel-
evance of plasma concentrations and genetic predis-
positions as moderators of neuropsychiatric compli-
cations.20 –25
The Food and Drug Administration8 reported results
from a sample of 1,008 patients with HIV who received
treatment with efavirenz, and it stated the probability of
“selected nervous-system symptoms of any severity”
regardless of causality as 52.7% compared with 24.6% in
a control group (HIV individuals not receiving efa-
virenz). The risk of discontinuation of treatment as a
result of experiencing symptoms was 2.1% in efavirenz-
treated patients compared with 1.1% in the control
group. On average, prevalence rates range from 40% to
70%.15,26–28 This wide range in prevalence estimates is
probably due to differences in study design (e.g., sam-
ple sizes, recruitment methods, and assessment of neu-
ropsychiatric complications) and methodological qual-
ity, but it is also due to the inconsistent use of terms
such as “CNS-related toxicity,” “psychiatric,” and
“neuropsychiatric,” and categorizing mental disorders
such as major depression or posttraumatic stress disor-
der using unspecified diagnostic criteria. To complicate
the picture further, few studies have used assessment
tools that are suitable for detecting efavirenz treatment-
associated complications on a subclinical level. Taking
into account such methodological differences in early
publications on efavirenz toxicity, reports on preva-
lence rates have since converged and remain relatively
stable; an average of one out of two patients receiving
efavirenz shows adverse psychiatric reactions. Repeat-
edly confirmed in numerous controlled trials, these
data refer to the incremental contribution of risk, which
cannot be explained by HIV-associated long-term brain
damage. In direct comparison to treatment alternatives,
adverse effects resulting from treatments including efa-
virenz are reported three times more often than in cases
of protease inhibitors.7
In terms of symptom manifestation over time, the
most severe toxicity effects of efavirenz treatment are
consistently reported to occur within the first 2–4 weeks
after efavirenz initiation,7 and symptoms generally
cease after 6–8 weeks.5,9 Long-term effects covering
periods of more than 12 weeks after efavirenz treatment
onset have rarely been investigated. Following a prag-
matic approach, studies have usually focused on clini-
cally relevant symptoms that could impact on medica-
tion adherence rather than the investigation of causal
pathways of the reported adverse reactions. Conse-
quently, most studies prioritized the application of as-
sessment tools and research designs suitable for the
diagnosis of mental disorders rather than the identifi-
cation of subclinical symptoms.
Subsequent research has reported mild and clinically
tolerable persistent impairments of psychological func-
tioning for up to 2 years after treatment onset.16 The
Efavirenz Consensus Working Group and other re-
searchers29,30 published recommendations for the treat-
ment of efavirenz-induced adverse effects, including
psychopharmacological treatment as well as nonphar-
macological symptom-specific management strategies
such as psychotherapeutic treatment.
Methodological Shortcomings in Previous Research
Research on efavirenz treatment-associated neuropsy-
chiatric toxicity suffers from a range of methodological
shortcomings, which have rarely been addressed in pre-
vious reviews. First, studies have often neglected the
assessment of a psychiatric baseline status, often due to
their retrospective design.31 Occasionally, interviewees
were asked to provide a retrospective report on their
mental status before treatment.32 In neither of the pub-
lished prospective studies was a psychiatric, psycholog-
ical, or neuropsychological baseline status before efa-
virenz treatment onset statistically controlled for,
although psychiatric history is considered a relevant
predictor for neuropsychiatric effects triggered by efa-
virenz. Second, the few published prospective studies
suffer from high attrition rates and are thus very likely
to underestimate the prevalence of psychiatric disor-
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ders in the actual outcome of clinical trials.27 This un-
derestimation is caused by selection biases and the
likely association of poor adherence and psychiatric dis-
orders at treatment onset, which is often not assessed.
Third, assessments in the form of semistructured inter-
views were applied by either researchers not blinded to
the treatment condition (e.g., prescribing physicians),
those without suitable training in the conduct of the
interview, or both.19 Fourth, in the vast majority of
studies, nonstandardized assessment tools were used or
measures applied that are insensitive for the detection
of prodromal symptoms.16,31,32
While the almost exclusive use of self-report mea-
sures in previous studies has enabled the identification
of clinically important symptoms, their lack of specific-
ity in relation to neurophysiological pathways does not
allow for any conclusions to be drawn about the mech-
anisms linking efavirenz and neuropsychiatric compli-
cations. In addition, assessment tools such as screening
tests and symptom checklists appear to be too insensitive
and too global to detect symptoms at the subclinical level.
These assessments are, therefore, likely to result in type II
error, particularly in monitoring more subtle long-term
effects. Statistical power, effect sizes, or both were rarely
reported, though this information would be crucial in or-
der to adequately assess the appropriateness of the ap-
plied assessment procedures and the severity of adverse
reactions in samples that range from single case studies to
large cohorts.
A particularly striking omission from previous re-
search investigating efavirenz treatment-associated side
effects concerns the almost complete lack of appropriate
neuropsychological assessments. The only published
and frequently cited studies claiming to have explicitly
investigated neuropsychological symptoms related to
efavirenz treatment are those from Clifford et al.33 and
von Giesen et al.31 Both studies conclude that neuro-
psychological symptoms did not occur or were only
mild and temporary. Nevertheless, the selection of
subtests from standardized assessment tools was not
theoretically justified in either study. For example,
Clifford et al.33 used composite scores (“NPZ3”) that
were inappropriately derived (adding subscores of
Trail Making tests A and B to the total of its subscales),
omitted crucial neuropsychological domains, and were
unspecific. These scores, therefore, do not allow for a
comprehensive assessment of the “neuropsychologi-
cal status” of patients with HIV. Furthermore, the
previously reported34 –37 observation that antiretro-
viral therapy leads to early improvements in motor-
related tasks impairs the interpretational power of
the results in terms of neuropsychological function-
ing.
von Giesen et al.31 used the “Kurztest zur Erfassung
von Geda¨chtnis- und Aufmerksamkeitsleistungen”
(Short Test for the Assessment of Memory and Atten-
tion Performance). This is a screening tool designed to
detect early dementia without sufficient differentiation
of memory and attention. It is, thus, insensitive to subtle
or moderate changes in cognitive function related to
efavirenz treatment, especially when compared to HIV
patients not receiving efavirenz but likely to show HIV-
related impairments. In addition, assessors were not
blinded to the treatment condition. The study is, there-
fore, methodically flawed, and its results (91% of par-
ticipants scored 0, “no severe cognitive impairment”)
are probably due to a floor effect. The authors’ conclu-
sion that “the present data do not provide evidence for
a higher incidence of light and/or severe neuropsychi-
atric side effects” (p. 382) associated with efavirenz
treatment is, therefore, questionable and unsupported
by their evidence.
In summary, no extensive or theory-driven neuropsy-
chological assessment has been attempted in studies on
efavirenz toxicity. Current conclusions regarding neu-
ropsychological performance have to be considered
premature and largely unsupported by evidence.
Following a bottom-up approach, recent research
has investigated the influence of the G516T polymor-
phism at the CYP2B6 isoenzyme on intracellular efa-
virenz plasma levels and has identified a CYP2B6
genotype as a predictor of efavirenz neuropsycholog-
ical toxicity.23,25 Patients with a homozygotic 516GT
substitution show higher efavirenz plasma levels and
report more frequent adverse reactions to efavirenz
treatment due to less effective intracellular drug clear-
ance compared with those carrying the wild type (GG).
These results could not be replicated in one other
study.22
Nevertheless, the findings from Lowenhaupt et al.23
and Rotger et al.25 point to the possibility that previous
investigations of efavirenz-related adverse effects may
have suffered from low statistical power as they did not
take into account inter-individual differences in drug
clearance capacity. Drug clearance or efavirenz plasma
levels are obvious moderators of any outcome in studies
investigating toxicity associated with efavirenz treatment.
Future research investigating causal pathways between
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efavirenz treatment and its adverse side effects should,
therefore, screen participants for carriers of the G516T
allele or include a measure of efavirenz clearance, or both,
in order to identify those subsamples with increased vul-
nerability because of slow drug clearance.
Questions Unanswered by Current Research
Efavirenz is only one of several regimens in the class
of retroviral inhibitors. Nevertheless, its extraordinary
effective penetration into the CNS and its unique ap-
proach to the inhibition of viral reverse transcriptase have
earned efavirenz the status of a first-line treatment despite
its significantly higher risk of neurologic toxicity com-
pared with other regimens of antiretroviral therapy. The
reasons why neuropsychiatric effects occur more fre-
quently and with greater severity during efavirenz treat-
ment than, for example, during treatment with the struc-
turally comparable nevirapine6,7 remain unclear, as the
identification of neural pathways and systems responsible
for these adverse effects is still pending.
Early case studies from the late 1990s and conference
contributions on toxicity related to efavirenz treat-
ment38 triggered a fast-growing pool of empirical data
feeding into early reviews on efavirenz toxicity,15 rec-
ommending the monitoring of CNS adverse effects in
all patients taking efavirenz. Psychiatric diagnoses,
however, often remained rather vague, with some pub-
lications citing merely anecdotal observations without
using standardized assessment methods or specified
diagnostic criteria. There was a preponderance of prag-
matic approaches in terms of risk management and the
development of practice guidelines. Research designs
and their implications were, therefore, rarely discussed.
This practice-oriented “bottom-up approach” can be
contrasted with a “top-down approach,” which links
the results on efavirenz treatment-associated symptoms
with theoretical models from the behavioral sciences.
Such an approach may contribute to a more compre-
hensive understanding of the complex interplay of cel-
lular level mechanisms and behavioral patterns.
We argue that a shift in focus from clinical treat-
ment-related toxicities to the development of a con-
ceptual framework would allow for the improvement
of screening methods for individuals at risk for ad-
verse reactions following efavirenz treatment. This
paradigm shift would also help to improve monitor-
ing methods (early alerts) and contribute to the de-
velopment of tests applied to detect neuropsychiatric
risk potential for future drugs taking effect in the
CNS.
Suggestion for a New Research Approach
Previous research on efavirenz treatment-associated
neuropsychiatric toxicity has been largely descrip-
tive, with the aim to identify, classify, and assess the
probability and severity of symptoms that may impair
treatment adherence for this effective and daily admin-
istered lifelong medication. Despite considerable im-
provements in risk management by including genotyp-
ing in medical decisions in vulnerable populations and
recommendations for risk management strategies, the
missing link between pathological symptoms and efa-
virenz has not been identified yet. Current research,
therefore, is confined to providing practice guidelines
for clinicians to maximize adherence rather than explor-
ing their origin (e.g., alternative treatment options, dose
reduction, prescription of antidepressants, and non-
pharmacological interventions).
We argue, therefore, for the development of a theory-
driven and standardized way of screening for neuro-
psychiatric toxicities in efavirenz and other antiretrovi-
ral agents. We suggest a top-down approach by
classifying and integrating typical efavirenz-related
symptoms such as depression, suicidal ideation, aggres-
sive/impulsive behavior, delusions, impaired concen-
tration, irritability, and nervousness into the psycholog-
ical concept of self-regulation. This approach
complements existing bottom-up research strategies in
medical research and makes use of the profile of clinical
symptomatology associated with efavirenz treatment,
indicating an impairment of functions which can
largely be conceptualized as behavioral, cognitive and
affective dysregulation (Figure 1).
Concepts and methods from psychophysiology and ex-
perimental and clinical neuropsychology can locate cur-
rent results in a theoretical framework, which will gener-
ate testable hypotheses that go beyond the selection of
appropriate assessment tools. Such a model would allow
for the identification of subtle effects of efavirenz on psy-
chophysiological levels, leading to the identification of the
neuronal networks affected. The similarities of efavirenz-
associated symptoms to syndromes observed in brain-
damaged patients with dysexecutive functions and their
involvement of systems of behavioral control suggest the
application of standard paradigms designed for neuro-
psychological profiling in patients with inhibition-related
impairments.39 Results from the neurosciences and psy-
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chology have established the capacity to self-regulate be-
havior, to resist impulses, and to regulate emotions effec-
tively as a personality trait.40 Behavioral neuroscience of
self-regulation links traditional psychological approaches
of behavioral theory with their neurological underpin-
nings and implies standardized assessment tools for fine-
grained analyses of cognitive and behavioral regulative
skills and their neuronal substrates, basically located in
the frontal cortex.41 Behavioral self-regulation is often un-
derstood as one of several functions within the broad and
sometimes fuzzy concept of executive functions. Research
on dysexecutive syndromes provides models and specific
experimental paradigms39 further supported by neuroim-
aging techniques which have not been used in efavirenz-
related research on psychiatric or psychological adverse
effects.42,43 Neuropsychological and psychophysiological
research on self-regulation makes use of assessment tech-
niques that detect and quantify subtle neuronal and phys-
iological processes relevant for behavioral control such as
frontal inhibitory functions.
To give a more specific example for potentially inter-
esting new research paradigms linking symptom obser-
vations with established psychophysiological research
paradigms, the assessment of peripheral parameters
such as cardiac autonomic balance might contribute to
a better understanding of behavioral dysregulation in
efavirenz-treated patients. The neuroanatomical con-
cept of central autonomic networks44,45 depicts a pro-
cess of neurovisceral integration in which peripheral
psychophysiological reactions (heart rate, salivation,
electrodermal reactions, and startle reflex potentiation)
are related to neocortical structures such as the prefron-
tal cortex (PFC) and cingulate cortex as well as subcor-
tical limbic areas (thalamus, hypothalamus, and amyg-
dalae), triggering autonomic reactions. The degree of
flexibility of this system is related to adaptive behavior,
including complex behavioral processes such as social
interaction. On a peripheral level, this is expressed by
vagal tone. Reciprocal cortico-cardiac interactions are
key features of the central autonomic networks and are
indicated by the sympathetic-parasympathetic inter-
play as it is expressed in heart rate variability. Auto-
nomic nervous system-related measures such as heart
rate variability or baroreceptor sensitivity can be con-
FIGURE 1. A New Research Paradigm for the Study of Efavirenz Treatment-Related Toxicities
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This theory-driven approach applies psychological models of behavioral regulation to observed manifestations of efavirenz treatment-
related toxicities. Psychophysiological concepts link the subjective and social perspective of human behavior and experience with
physiological correlates, which can be systematically assessed using standardized techniques. Empirical evidence for neuropsychological
underpinnings of psychophysiological phenomena provides theoretical connections to neuronal activity patterns resulting in maladaptive
behavior. A comprehensive approach making use of psychophysiological heuristics offers standardized and practical tools which might be
applied in screening, monitoring, and fundamental research.
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ceived as a proxy for sympatho-vagal-balance, and due
to their neuroanatomic relation to the PFC, they also
indicate an individual’s self-regulative capacities.46,47
Observed deficits in behavioral regulation as de-
scribed in cases of efavirenz-induced neuropsychiatric
reactions fit well into the psychological concepts of self-
regulation, which cognitive neuroscience interprets as
behavioral correlates of executive functions associated
with the PFC, the ventro-medial PFC, and the cingulate
cortex. These neuronal correlates and their correspond-
ing autonomic functions, as predicted in central auto-
nomic network theory, allow the deployment of estab-
lished and standardized assessment tools. Hence, by
applying new theory-driven research approaches,
drug-induced behavioral abnormalities can be illumi-
nated, screening methods improved, and treatment op-
tions considered.
The concept of central autonomic networks empha-
sizes the reciprocal interactions between (prefrontal)
cortical and cardiac processes and is in line with frontal
hypofunction in patients who show symptoms of be-
havioral, affective, or cognitive dysregulation. Making
use of the reciprocity of the central-autonomic net-
works, an exemplary application of this concept could
involve biofeedback of heart rate variability or respira-
tory sinus arrhythmia. This method is easy to use and
has established efficacy in the treatment of depression48
and anxiety disorders.49 The reciprocity of cortico-car-
diac interactions, based on cortical plasticity, provides
opportunities for behavioral interventions.50,51
Electrophysiological correlates of behavior (e.g.,
event-related potentials) illuminate features of cogni-
tive top-down and bottom-up processes such as evalu-
ation, categorization, orienting/alertness, or novelty
and are sensitive to pharmacological treatments. Sev-
eral features such as amplitude and latency of event-
related potentials can be linked to behavioral or cogni-
tive dysregulation. Response inhibition paradigms
combine behavioral tasks requiring motor inhibition in
standardized and well-established paradigms such as
Go-NoGo,48,49 stop-signal,53 or others with correspond-
ing electrophysiological measures such as N200 ampli-
tude.54 A sensitive measure such as the inhibition-re-
lated N200 event-related potential may be able to assess
subclinical changes in cognitive and behavioral regula-
tion processes,55 which have been suggested to be based
on a supermodal inhibition-eliciting initiatior in the
right inferior prefrontal cortex and, therefore, to be
closely linked to cognitive adaptivity and flexibility.56,57
Symptomatic manifestations of dysregulated behavior
typically following efavirenz toxicity suggest this meth-
od’s relevance for possibly related symptoms for phar-
macological treatment. The neural generators, which
compose the N200 and the relevance of these anatomi-
cal structures for behavioral and cognitive regulation,
are well researched. The same applies to other event-
related potentials occurring early or late over the time
course. They indicate features of cognitive processing
and thus provide a quantitative assessment with much
higher temporal resolution than through solely behav-
ioral observation, though their selection is based on
self-report information.
The methods outlined above are examples of stan-
dardized tools that assess behavioral and emotional
regulation. They have been shown to contribute to a bet-
ter understanding of a variety of affective and behavioral
disorders covering the same class of symptoms of disin-
hibition as described in the literature on efavirenz side
effects (e.g., impulsivity,58 affective disorders,59,60 psycho-
pathology in general44,61 and various other psychiatric
symptoms, impairments of executive functions,39,42,43,59
and cognitive performance62) (Table 1).
Models of and empirical findings on executive func-
tions and their relation to frontal inhibition and behav-
ioral regulation42 can provide an extensive framework
for behavioral regulation. Such concepts link neuroana-
tomical structures and psychophysiological processes
with observable behavior in everyday life63,64 and en-
able researchers to a theory-driven choice of specific
and sensitive assessment methods.
We hope this new research approach will help to
improve guidelines for efavirenz treatment by provid-
ing more sensitive assessment tools (i.e., those that are
able to detect subtle subclinical changes, thus enabling
practitioners to prevent or minimize treatment-associ-
ated adverse effects). We further expect progress in
research on the identification of persons at risk for ad-
verse effects of efavirenz treatment and argue for the
introduction of paradigms developed in behavioral sci-
ences to be applied in research on drug side effects with
psychological and psychiatric implications.
CONCLUSION
In this review we suggest a change in research para-
digms and conceptualize efavirenz-related side effects
as manifestations of behavioral dysregulation. We pro-
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pose to extend current research strategies to a theory-
driven top-down process tying together existing knowl-
edge on self-regulation theory. Previous research on
efavirenz toxicity is restricted to purely descriptive ap-
proaches at the symptom level. By suggesting a top-
down, theory-driven strategy we argue for applying
established and standardized assessment tools, which
are provided by the psychophysiological concepts of
self-regulation. The aims of this reconceptualization are
the improvement of screening methods for the identi-
fication of patients at risk for efavirenz treatment-re-
lated side effects, the enhancement of fundamental re-
search on self-regulation-related effects of
pharmacological substances passing the blood-brain
barrier, and the establishment of effective and close
monitoring during treatment. This approach enables
researchers to tap into established knowledge in or-
der to choose specific and sensitive psychophysiolog-
ical assessment tools based on hypotheses derived
from observation and self-reports of previous re-
search. The use of psychophysiological measures in
the assessment process enables the quantification of
treatment-related side effects with high temporal so-
lution, comparative measurements, and sensitivity
toward subclinical effects, and thus provides a new
source of information.
The assessment methods suggested here are estab-
lished and standardized; data for various common psy-
chological and psychiatric disorders frequently de-
scribed as efavirenz-related adverse effects are
available. This will generate hypotheses for risk assess-
ment and risk management, screening methods, moni-
toring, and prescription criteria and opens new per-
spectives for the investigation of neuronal networks
and pathways. We argue that the identification and
quantification of efavirenz treatment-related subtle and
subclinical changes on cognitive, behavioral, and emo-
tional levels are crucial for substantial progress from
purely descriptive approaches of the past toward an
understanding of psychopharmacological effects. These
subtle changes require appropriate research designs
(controlled, double-blinded) and standardized assess-
ment tools beyond behavioral observation and self-re-
port in order to tap into existing knowledge of behav-
ioral regulation and its origins. This approach and its
related methodology address serious limitations in cur-
rent research by bridging the gap between fundamental
research in neurobiological domains and behavioral sci-
ences.
This paper has benefitted in its early stages from discus-
sions with Dr. Rupert Whitaker, Tuke Institute, London.
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